Toxicities encountered during tipifarnib plus etoposide therapy
| Toxicity . | Cycle 1 (% of 84 patients) . | Total (% of 224 cycles) . |
|---|---|---|
| Hospitalizations | 42 (50%) | 59 (26%) |
| Documented infections | 25 (30%) | 36 (16%) |
| Skin/cellulitis | 7 | 9 |
| Pneumonia | 6 | 10 |
| Sinusitis | 2 | 3 |
| Pharyngitis/esophagitis | 3 | 3 |
| Gastrointestinal | 1 | 4 |
| Genitourinary | 3 | 3 |
| Bacteremia (no site) | 3 | 4 |
| Neutropenic fever | 20 (24%) | 30 (13%) |
| Drug-related toxicities | ||
| Neurotoxicity (grades 1-3) | 12 (14%)* | 20 (9%)† |
| Mucositis (grade > 2) | 10 (12%) | 12 (5%) |
| Gastrointestinal (grade > 2) | 9 (11%) | 12 (5%) |
| Hyperbilirubinemia (grade > 2) | 4 (5%) | 6 (3%) |
| Renal (grade > 2) | 3 (4%) | 4 (2%) |
| Rash (grade > 2) | 4 (5%) | 6 (3%) |
| Fatigue (grade > 2) | 6 (7%) | 12 (5%) |
| Cardiac (grades 1-5) | 3 (4%)‡ | 8 (4%)§ |
| Death | 9 (11%) | 13 (5.8%) |
| Infection | 5 | 5 |
| Cardiac | 1 | 4 |
| Cerebrovascular | 1 | 2 |
| Pulmonary | 2 | 2 |
| Toxicity . | Cycle 1 (% of 84 patients) . | Total (% of 224 cycles) . |
|---|---|---|
| Hospitalizations | 42 (50%) | 59 (26%) |
| Documented infections | 25 (30%) | 36 (16%) |
| Skin/cellulitis | 7 | 9 |
| Pneumonia | 6 | 10 |
| Sinusitis | 2 | 3 |
| Pharyngitis/esophagitis | 3 | 3 |
| Gastrointestinal | 1 | 4 |
| Genitourinary | 3 | 3 |
| Bacteremia (no site) | 3 | 4 |
| Neutropenic fever | 20 (24%) | 30 (13%) |
| Drug-related toxicities | ||
| Neurotoxicity (grades 1-3) | 12 (14%)* | 20 (9%)† |
| Mucositis (grade > 2) | 10 (12%) | 12 (5%) |
| Gastrointestinal (grade > 2) | 9 (11%) | 12 (5%) |
| Hyperbilirubinemia (grade > 2) | 4 (5%) | 6 (3%) |
| Renal (grade > 2) | 3 (4%) | 4 (2%) |
| Rash (grade > 2) | 4 (5%) | 6 (3%) |
| Fatigue (grade > 2) | 6 (7%) | 12 (5%) |
| Cardiac (grades 1-5) | 3 (4%)‡ | 8 (4%)§ |
| Death | 9 (11%) | 13 (5.8%) |
| Infection | 5 | 5 |
| Cardiac | 1 | 4 |
| Cerebrovascular | 1 | 2 |
| Pulmonary | 2 | 2 |